Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Evaluation of Allied Healthcare in Patients Recovering From COVID-19 (ParaCOV)

9 de maio de 2022 atualizado por: Radboud University Medical Center

SUMMARY Rationale: Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) might play an important role in the recovery of patients with COVID-19 who experience limitations in daily physical functioning and participation. However, the evidence base for allied healthcare in patients with COVID-19 has yet to be established. To facilitate care for people recovering from COVID-19 and to establish this evidence base, the Dutch ministry has created a temporary regulation for primary care allied healthcare specifically for patients with COVID-19.

Objective: This study is setup alongside the temporary regulation and aims to evaluate the longitudinal recovery trajectories and related costs of patients who visited a primary care allied healthcare professional for the management of severe symptoms and activity limitations and/or participation restrictions related to COVID-19.

Study design: Prospective cohort study. Study population: 1,315 adult patients recovering from COVID-19 with severe symptoms and activity limitations and/or participation restrictions, and who are referred to a primary care allied health professional by a general practitioner or medical specialist within four months of the start of the disease will be eligible for this study.

Intervention (if applicable): Although the nature of this study is non-experimental, the allied healthcare intervention can be considered experimental due to the novelty of the disease.

Main study parameters/endpoints: The primary outcome domain of this study is participation measured with the Utrechtse Schaal voor Revalidatie - Participatie (USER-P). The primary endpoint is set at 6 months. A 5 point difference will be considered clinically relevant for patients with COVID-19.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: There are no specific risks involved with participation in this study, as it entails the completion of questionnaires over the timeframe of one year (at the start of the treatment, the end of the treatment, 3 months, 6 months, 9 months and 12 months). The load of the survey will be highest at months 3, 6 and 12 with a total of 74 survey items. Input from patient representatives suggested that this number of items was feasible, especially because participants are allowed to complete the survey over a number of days. Finally, none of the items in the survey are considered emotionally distressing. The prescribed interventions are conform the recommendations of the best available evidence and are in line with usual allied healthcare interventions. Therefore, risks are likely to be negligible conform usual allied healthcare.

Visão geral do estudo

Tipo de estudo

Observacional

Inscrição (Real)

1441

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Gelderland
      • Nijmegen, Gelderland, Holanda, 6500HB
        • Radboud University Medical Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

N/D

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra de Probabilidade

População do estudo

Adult patients of 18 year and older recovering from COVID-19 with severe symptoms and activity limitations and/or participation restrictions, who are referred to a primary care allied health professional* by a general practitioner or medical specialist are deemed eligible for this study.

*Allied health professionals relevant to this study are: Dietitians, Exercise Therapists, Occupational Therapists, Physical Therapists, and Speech and Language Therapists working in primary care in the Netherlands.

Descrição

Inclusion Criteria:

Adult patients

  • recovering from COVID-19 with severe symptoms and activity limitations and/or participation restrictions, and;
  • who are referred to a primary care allied health professional by a general practitioner or medical specialist within four months of the start of the disease; will be eligible for this study. The need for referring the patient to an allied health professional will be judged by the primary care physician or medical specialist. Criteria for referral are described in guidance published by the Long Alliantie Nederland (LAN) with recommendations for treatment of post-COVID-19-patients: the COVID-19 Associated Syndrome (CAS) (Chapters 3.3 and 4).

http://www.longalliantie.nl/files/2515/9359/4621/Handreiking_voor_de_zorg.pdf

Exclusion Criteria:

Adult patients:

- receiving palliative care; are excluded from this study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Prospective cohort
Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) that treat patients recovering from COVID-19 in Dutch primary care
We will not develop specific interventions for this prospective observational cohort study. The care provided by allied health professionals in daily practice are based on recommendations published by the professional bodies of allied health professionals and on the interdisciplinary guidance developed by the LAN. All allied health professionals are working according to these recommendations. Dissemination of these recommendations is done by the professional bodies of the allied health professionals. Given the observational nature of our study, no additional implementation strategies will be employed to stimulate this care by the research group.
Retrospective cohort
Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) that have been treated patients recovering from COVID-19 in Dutch primary care
We will not develop specific interventions for this prospective observational cohort study. The care provided by allied health professionals in daily practice are based on recommendations published by the professional bodies of allied health professionals and on the interdisciplinary guidance developed by the LAN. All allied health professionals are working according to these recommendations. Dissemination of these recommendations is done by the professional bodies of the allied health professionals. Given the observational nature of our study, no additional implementation strategies will be employed to stimulate this care by the research group.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Participation
Prazo: Baseline (T0)
Measured with the Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P) (32 items)
Baseline (T0)
Participation
Prazo: 3 months (T1)
Measured with the Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P) (32 items)
3 months (T1)
Participation
Prazo: 6 months (T2)
Measured with the Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P) (32 items)
6 months (T2)
Participation
Prazo: 12 months (T3)
Measured with the Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P) (32 items)
12 months (T3)
Quality of life measured with EQ-5D-5L
Prazo: Baseline (T0)
Measured with the EuroQol five-dimensional questionnaire (EQ-5D-5L) (5 items)
Baseline (T0)
Quality of life measured with EQ-5D-5L
Prazo: 3 months (T1)
Measured with the EuroQol five-dimensional questionnaire (EQ-5D-5L) (5 items)
3 months (T1)
Quality of life measured with EQ-5D-5L
Prazo: 6 months (T2)
Measured with the EuroQol five-dimensional questionnaire (EQ-5D-5L) (5 items)
6 months (T2)
Quality of life measured with EQ-5D-5L
Prazo: 12 months (T3)
Measured with the EuroQol five-dimensional questionnaire (EQ-5D-5L) (5 items)
12 months (T3)
Fatigue
Prazo: Baseline (T0)
Measured with the Fatigue Severity Scale (FSS)
Baseline (T0)
Fatigue
Prazo: 3 months (T1)
Measured with the Fatigue Severity Scale (FSS)
3 months (T1)
Fatigue
Prazo: 6 months (T2)
Measured with the Fatigue Severity Scale (FSS)
6 months (T2)
Fatigue
Prazo: 12 months (T3)
Measured with the Fatigue Severity Scale (FSS)
12 months (T3)
Physical functioning
Prazo: Baseline (T0)
PROMIS Physical Functioning Short Form 10b (10 items).
Baseline (T0)
Physical functioning
Prazo: 3 months (T1)
PROMIS Physical Functioning Short Form 10b (10 items).
3 months (T1)
Physical functioning
Prazo: 6 months (T2)
PROMIS Physical Functioning Short Form 10b (10 items).
6 months (T2)
Physical functioning
Prazo: 12 months (T3)
PROMIS Physical Functioning Short Form 10b (10 items).
12 months (T3)
Costs
Prazo: Baseline (T0)
will be measured using a cost questionnaire (18 items)
Baseline (T0)
Costs
Prazo: 3 months (T1)
will be measured using a cost questionnaire (18 items)
3 months (T1)
Costs
Prazo: 6 months (T2)
will be measured using a cost questionnaire (18 items)
6 months (T2)
Costs
Prazo: 9 months (T3)
will be measured using a cost questionnaire (18 items)
9 months (T3)
Costs
Prazo: 12 months (T4)
will be measured using a cost questionnaire (18 items)
12 months (T4)
Patient Specific Activities
Prazo: baseline (T0) as part of usual care
measured with the Patient Specific Complaints (PSC)
baseline (T0) as part of usual care
Patient Specific Activities
Prazo: end of the treatment as part of usual care (average of 6 months)
measured with the Patient Specific Complaints (PSC)
end of the treatment as part of usual care (average of 6 months)
Nutritional Status
Prazo: baseline (T0) as part of usual care
measured with the BMI (weight and height)
baseline (T0) as part of usual care
Nutritional Status
Prazo: end of the treatment as part of usual care (average of 6 months)
measured with the BMI (weight and height)
end of the treatment as part of usual care (average of 6 months)
Global Assessment
Prazo: baseline (T0) as part of usual care
measured with the PG-SGA short form weight history, food intake, symptoms, activities and function).
baseline (T0) as part of usual care
Global Assessment
Prazo: end of the treatment as part of usual care (average of 6 months)
measured with the PG-SGA short form weight history, food intake, symptoms, activities and function).
end of the treatment as part of usual care (average of 6 months)
Voice Problems
Prazo: baseline (T0) as part of usual care
measured with Voice Handicap Index (VHI)
baseline (T0) as part of usual care
Voice Problems
Prazo: end of the treatment as part of usual care (average of 6 months)
measured with Voice Handicap Index (VHI)
end of the treatment as part of usual care (average of 6 months)
Swallowing Problems
Prazo: baseline (T0) as part of usual care
Dysphagia Handicap Index (DHI).
baseline (T0) as part of usual care
Swallowing Problems
Prazo: end of the treatment as part of usual care (average of 6 months)
Dysphagia Handicap Index (DHI).
end of the treatment as part of usual care (average of 6 months)
Patient Specific Activities
Prazo: baseline (T0) as part of usual care
measured with the Canadian Occupational Performance Measure (COPM)
baseline (T0) as part of usual care
Patient Specific Activities
Prazo: end of the treatment as part of usual care (average of 6 months)
measured with the Canadian Occupational Performance Measure (COPM)
end of the treatment as part of usual care (average of 6 months)
Activities
Prazo: baseline (T0) as part of usual care
measured with the PRO-ergo
baseline (T0) as part of usual care
Activities
Prazo: end of the treatment as part of usual care (average of 6 months)
measured with the PRO-ergo
end of the treatment as part of usual care (average of 6 months)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Exercise capacity
Prazo: baseline (T0) as part of usual care
6 Minute Walk Test (6MWT)
baseline (T0) as part of usual care
Exercise capacity
Prazo: end of the treatment as part of usual care (average of 6 months)
6 Minute Walk Test (6MWT)
end of the treatment as part of usual care (average of 6 months)
Exercise capacity
Prazo: baseline (T0) as part of usual care
Short Physical Performance Battery (SPPB)
baseline (T0) as part of usual care
Exercise capacity
Prazo: end of the treatment as part of usual care (average of 6 months)
Short Physical Performance Battery (SPPB)
end of the treatment as part of usual care (average of 6 months)
Quadriceps strength
Prazo: baseline (T0) as part of usual care
with a hand dynamometer.
baseline (T0) as part of usual care
Quadriceps strength
Prazo: end of the treatment as part of usual care (average of 6 months)
with a hand dynamometer.
end of the treatment as part of usual care (average of 6 months)
Hand grip strength
Prazo: baseline (T0) as part of usual care
with a hand dynamometer.
baseline (T0) as part of usual care
Hand grip strength
Prazo: end of the treatment as part of usual care (average of 6 months)
with a hand dynamometer.
end of the treatment as part of usual care (average of 6 months)
Bioimpedance (BIA
Prazo: baseline (T0) as part of usual care
baseline (T0) as part of usual care
Bioimpedance (BIA
Prazo: end of the treatment as part of usual care (average of 6 months)
end of the treatment as part of usual care (average of 6 months)
VAS-appetite, taste and smell
Prazo: baseline (T0) as part of usual care
baseline (T0) as part of usual care
VAS-appetite, taste and smell
Prazo: end of the treatment as part of usual care (average of 6 months)
end of the treatment as part of usual care (average of 6 months)
Dietary goal attainment
Prazo: baseline (T0) as part of usual care
baseline (T0) as part of usual care
Dietary goal attainment
Prazo: end of the treatment as part of usual care (average of 6 months)
end of the treatment as part of usual care (average of 6 months)
Liquid medical nutrition
Prazo: baseline (T0) as part of usual care
baseline (T0) as part of usual care
Liquid medical nutrition
Prazo: end of the treatment as part of usual care (average of 6 months)
end of the treatment as part of usual care (average of 6 months)
Sarcopenia
Prazo: baseline (T0) as part of usual care
measured with the SARC-F
baseline (T0) as part of usual care
Sarcopenia
Prazo: end of the treatment as part of usual care (average of 6 months)
measured with the SARC-F
end of the treatment as part of usual care (average of 6 months)
Types of Stool
Prazo: baseline (T0) as part of usual care
measured with the Bristol Stool Chart (BCS)
baseline (T0) as part of usual care
Types of Stool
Prazo: end of the treatment as part of usual care (average of 6 months)
measured with the Bristol Stool Chart (BCS)
end of the treatment as part of usual care (average of 6 months)
Voice Problems
Prazo: baseline (T0) as part of usual care
measured with Maximum Phonation Time (MPT)
baseline (T0) as part of usual care
Voice Problems
Prazo: end of the treatment as part of usual care (average of 6 months)
measured with Maximum Phonation Time (MPT)
end of the treatment as part of usual care (average of 6 months)
Swallowing Problems
Prazo: baseline (T0) as part of usual care
measured with Maximum Swallowing Speed (MSP)
baseline (T0) as part of usual care
Swallowing Problems
Prazo: end of the treatment as part of usual care (average of 6 months)
measured with Maximum Swallowing Speed (MSP)
end of the treatment as part of usual care (average of 6 months)
Physical Functioning
Prazo: baseline (T0) as part of usual care
measured with the Assessment of Motor and Process Skills (AMPS)
baseline (T0) as part of usual care
Physical Functioning
Prazo: end of the treatment as part of usual care (average of 6 months)
measured with the Assessment of Motor and Process Skills (AMPS)
end of the treatment as part of usual care (average of 6 months)
Cognitive Functioning
Prazo: baseline (T0) as part of usual care
measured with the Cognitive Complaints - Participation (CoCo-P)
baseline (T0) as part of usual care
Cognitive Functioning
Prazo: end of the treatment as part of usual care (average of 6 months)
measured with the Cognitive Complaints - Participation (CoCo-P)
end of the treatment as part of usual care (average of 6 months)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Philip van der Wees, Prof. dr., Radboud University Medical Center

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

29 de março de 2021

Conclusão Primária (Antecipado)

17 de julho de 2022

Conclusão do estudo (Antecipado)

1 de janeiro de 2024

Datas de inscrição no estudo

Enviado pela primeira vez

28 de janeiro de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de fevereiro de 2021

Primeira postagem (Real)

3 de fevereiro de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

10 de maio de 2022

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de maio de 2022

Última verificação

1 de maio de 2022

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Covid19

3
Se inscrever